Diaceutics PLC

AIM:DXRX Stock Report

Market Cap: UK£106.0m

Diaceutics Future Growth

Future criteria checks 3/6

Diaceutics is forecast to grow earnings and revenue by 83.5% and 1.8% per annum respectively while EPS is expected to grow by 81% per annum.

Key information

83.5%

Earnings growth rate

81.0%

EPS growth rate

Life Sciences earnings growth19.7%
Revenue growth rate1.8%
Future return on equityn/a
Analyst coverage

Good

Last updated17 Dec 2024

Recent future growth updates

Recent updates

Diaceutics PLC (LON:DXRX) Stock Rockets 29% But Many Are Still Ignoring The Company

May 30
Diaceutics PLC (LON:DXRX) Stock Rockets 29% But Many Are Still Ignoring The Company

Diaceutics PLC's (LON:DXRX) Subdued P/S Might Signal An Opportunity

Jan 31
Diaceutics PLC's (LON:DXRX) Subdued P/S Might Signal An Opportunity

Industry Analysts Just Made A Notable Upgrade To Their Diaceutics PLC (LON:DXRX) Revenue Forecasts

Jan 28
Industry Analysts Just Made A Notable Upgrade To Their Diaceutics PLC (LON:DXRX) Revenue Forecasts

Estimating The Intrinsic Value Of Diaceutics PLC (LON:DXRX)

Jul 24
Estimating The Intrinsic Value Of Diaceutics PLC (LON:DXRX)

Would Shareholders Who Purchased Diaceutics' (LON:DXRX) Stock Year Be Happy With The Share price Today?

Feb 04
Would Shareholders Who Purchased Diaceutics' (LON:DXRX) Stock Year Be Happy With The Share price Today?

Here's Why We Don't Think Diaceutics's (LON:DXRX) Statutory Earnings Reflect Its Underlying Earnings Potential

Dec 31
Here's Why We Don't Think Diaceutics's (LON:DXRX) Statutory Earnings Reflect Its Underlying Earnings Potential

Do Insiders Own Lots Of Shares In Diaceutics PLC (LON:DXRX)?

Nov 27
Do Insiders Own Lots Of Shares In Diaceutics PLC (LON:DXRX)?

Earnings and Revenue Growth Forecasts

AIM:DXRX - Analysts future estimates and past financials data (GBP Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20264767104
12/31/2025381166
12/31/202430-2-326
6/30/202426-3-22N/A
3/31/202425-2-32N/A
12/31/202324-2-41N/A
9/30/202323-1-32N/A
6/30/2023220-33N/A
3/31/2023210-14N/A
12/31/202220105N/A
9/30/2022180N/AN/AN/A
6/30/2022160-33N/A
3/31/2022150-42N/A
12/31/2021141-51N/A
9/30/2021140N/AN/AN/A
6/30/202113-1-60N/A
3/31/2021130-60N/A
12/31/2020130-60N/A
9/30/2020142-51N/A
6/30/2020143-41N/A
3/31/2020142-40N/A
12/31/2019130-4-1N/A
9/30/2019120-30N/A
6/30/2019110-20N/A
3/31/2019110-2-1N/A
12/31/2018101-2-1N/A
12/31/201771N/A2N/A
12/31/201651N/A1N/A
12/31/201510N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DXRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.1%).

Earnings vs Market: DXRX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: DXRX is expected to become profitable in the next 3 years.

Revenue vs Market: DXRX's revenue (1.8% per year) is forecast to grow slower than the UK market (3.6% per year).

High Growth Revenue: DXRX's revenue (1.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if DXRX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 19:01
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Diaceutics PLC is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hayley PalmerCanaccord Genuity
Colin SmithCapital Access Group
Oliver JugginsCapital Access Group